SCHEMBL5690364

SCHEMBL5690364

Cc1ccnc(CCc2ccc(OC(=O)N3CCC(On4cccn4)CC3)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.39
NOS2 P35228 2/20 0.39
NOS3 P29474 1/20 0.39
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KCNH2 Q12809 1/20 0.37
SCN5A Q14524 1/20 0.37
SCN9A Q15858 1/20 0.37
GAA P10253 1/20 0.36
GRIN2B Q13224 4/20 0.36
NPY2R P49146 1/20 0.36
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
P2RX3 P56373 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5687809 0.92 NOS3 (0.39) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5688040 0.88 GRIN2B (0.42) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5687592 0.88 AOC3 (0.40) TLR9TLR8TLR7NPC1RAB9A
SCHEMBL5691076 0.85 NOS1 (0.38) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5688265 0.85 KMT2A (0.41) NPC1RAB9AGAANPY2R
SCHEMBL5687686 0.83 RAB9A (0.38) NPC1RAB9AGAAGRIN2BNPY2R
SCHEMBL5688310 0.81 EPHX2 (0.44) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5688596 0.81 SRD5A2 (0.44) NOS1NOS2NOS3NPC1RAB9A
SCHEMBL5690538 0.81 GRIN2B (0.38) TLR9TLR8TLR7NPC1RAB9A
SCHEMBL5690515 0.81 RAB9A (0.42) NOS2NPC1RAB9AGAANPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC NOS1 646/4885NOS2 797/4885NOS3 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.